|
|
||||||||
Gastrointestinal Research Group, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
A key cell that has long been thought to play a major role in the development of type I IgE-mediated hypersensitivity to allergen is the mast cell (2, 3). These cells lie juxtaposed to the microcirculation, and their mediators can elicit enhanced microvascular permeability and up-regulate the adhesion molecules required for the recruitment of leukocytes (4, 5). In addition, the leukocyte infiltration observed 6 h after Ag challenge in normal mice skin is virtually undetectable in genetically mast cell-deficient mice (3). However, several studies suggest that mast cell degranulation is not the only mechanism involved in hypersensitivity reactions (6, 7, 8, 9, 10). For example, several groups have reported that fatal systemic IgG- or IgE-mediated anaphylaxis can be elicited in mast cell-deficient mice (7, 8, 9). It is possible that the small number of mast cells present in W/Wv mice (<1% in skin; none elsewhere) is sufficient to induce fatal anaphylactic shock. However, another more likely possibility is that other cells or cell types are involved in allergic responses.
The mast cell-independent mechanisms in immediate hypersensitivity reactions are unknown. However, platelets have been evoked in delayed-type hypersensitivity (T cell-mediated) reactions (6). Although it is not known currently whether platelets are involved in immediate hypersensitivity reactions, platelets have been described as having Fc
RII (Fc
RII/CD23) on their plasma membranes (11, 12, 13) that can bind IgE with low affinity. In addition, platelets have Fc
R (14), which may also participate in allergic immune response (15). Platelets contain granules that contain mediators that can increase vascular permeability such as serotonin (5-hydroxytryptamine (5-HT)),3 as well as chemotactic factors such as platelet-activating factor4 (PAF4) and many other proinflammatory mediators (16). In addition, platelets may play a role in amplifying the inflammatory response by cooperating with other cells, such as the neutrophil, to increase the production of chemotactic factors (17, 18). In vitro, leukocytes have been shown to roll and adhere on activated platelet monolayers, demonstrating the potential for platelets to assist in the recruitment of leukocytes from the circulation (19). In vivo, TNF-
induced significant platelet paving of brain pial endothelium and leukocyte rolling and adhesion, which could be attenuated by pretreatment with anti-platelet Ab (20). However, in response to the same provocation (TNF-
) in the skin, platelet depletion did not attenuate polymorphonuclear infiltration, suggesting the role of platelets in leukocyte recruitment may be tissue dependent (21). The reason for this is not determined to date.
In this study, we use intravital microscopy to allow direct visualization of the immediate allergic response in vivo, especially vascular permeability changes and immediate effects on leukocyte recruitment. Studies to date have used retrospective techniques such as edema formation and histological analysis to study these parameters. We evaluated changes in vascular permeability and leukocyte recruitment in skeletal muscle and skin in wild-type (WT) and mast cell-deficient (W/Wv) mice. Skeletal muscle represents a significant portion of the body mass and may be implicated in fatal anaphylactic responses. We compare these results with allergic responses in the skin, where mast cells have been shown to play a prominent role. Our results show that immediate allergen-induced vascular responses (increased permeability) and late phase leukocyte recruitment can occur in the absence of mast cells in skeletal muscle. We show for the first time that it is indeed the platelets that increase both allergen-induced permeability and leukocyte recruitment in mast cell-deficient muscle.
| Materials and Methods |
|---|
|
|
|---|
Male mast cell-deficient WBB6F1-KitW/KitW-v (W/Wv) mice and their WT congenic normal WBB6F1 (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice weighed between 20 and 30 g and were used between 6 and 10 wk of age. Harlan Sprague Dawley rats (Indianapolis, IN) were used for passive anaphylaxis reactions to check mice for OVA sensitization, as described below. Animal protocols were approved by the University of Calgary Animal Care Committee and met the Canadian Guidelines for Animal Research.
OVA sensitization
A type I hypersensitivity reaction was elicited by systemically (i.p. injection) sensitizing animals with 10 µg of chicken OVA (Sigma-Aldrich, St. Louis, MO) and 10 mg of grade V AlOH3 (Sigma-Aldrich) in a total volume of 0.2 ml of saline. Sham-sensitized mice received an i.p. injection of saline alone. Mice were challenged 2 wk later with either OVA or saline (sham), as described in experimental protocol section below.
Passive cutaneous anaphylaxis reaction
Serum was obtained from all OVA-sensitized animals at the end of the experiment by intracardiac puncture. Serial dilutions (1:81:64) of the serum samples were prepared, and 200 µl of each sample was injected intradermally into the shaved backs of Harlan Sprague Dawley rats. After 72 h, animals were challenged with an intracardiac injection of a solution containing 2.5 mg of Evans blue dye and 5 mg of chicken OVA in a total volume of 1.5 ml (saline). The final reaction was read 60 min later as the highest dilution that produced a distinct blue region (Evans blue dye extravasation) at the center of the injection site (22). The majority of sensitized mice had serum anti-OVA Ab titers of 1:64; 74% of WT, and 91% of W/Wv. The remaining mice had titers of 1:32 and were randomly distributed throughout the groups. Sham-sensitized animals had no anti-OVA Ab.
Intravital microscopy
Animals were anesthetized with an i.p. injection of a mixture of 10 mg/kg xylazine (MTC Pharmaceuticals, Cambridge, Ontario, Canada) and 200 mg/kg ketamine hydrochloride (Rogar/STB, Montreal, Quebec, Canada). For all protocols, the left jugular vein was cannulated to administer additional anesthetic or fluorescent dyes, if necessary. Animals were then prepared to view either the dermal (skin flap) or the skeletal muscle (cremaster) microcirculation.
Skin flap preparation. A midline dorsal incision was made. The skin was carefully separated from the underlying tissue, remaining attached laterally. Blood supply to the skin flap remained intact. The skin flap was then extended over a viewing pedestal, secured along the edges using 4-0 suture exposing the dermal microvasculature. The exposed skin was continuously superfused with warm bicarbonate-buffered saline (pH 7.4) to avoid tissue dehydration.
Cremaster preparation. An incision was made in the scrotal skin to expose the left cremaster muscle, which was then carefully removed from the associated fascia. A lengthwise incision was made on the ventral surface of the cremaster muscle using a cautery. The testicle and the epididymis were separated from the underlying muscle and moved into the abdominal cavity. The muscle was then spread out over an optically clear viewing pedestal and secured along the edges with 4-0 suture. The exposed tissue was superfused with warm bicarbonate-buffered saline (pH 7.4).
The dermal and cremasteric microcirculations were observed through an intravital microscope (Optiphot-2; Nikon, Tokyo, Japan) with a x40 water immersion lens (skin flap; 40/0.55 water immersion; Nikon) or a x25 objective lens (skeletal muscle; L25/0.35 Leitz Wetzlar, Munich, Germany) and a x10 eyepiece. The cremasteric microcirculation was transilluminated, and images were recorded using a video camera (Panasonic 5100 HS, Osaka, Japan). Due to thickness of the skin flap, leukocyte-endothelial cell interactions were not visible by transillumination. Therefore, for this protocol, animals were injected with the fluorescent dye, rhodamine 6G (0.3 mg/kg i.v.; Sigma-Aldrich), immediately before microscopic visualization. Rhodamine 6G at the dose used labels leukocyte and platelets and has been shown to allow detection of the same number of rolling leukocyte as transmitted light and have no effect on leukocyte kinetics (23, 24). This allows for quantification of leukocyte rolling flux and adhesion via epifluorescence microscopy. Rhodamine 6G-associated fluorescence was visualized by epi-illumination at 510560 nm using a 590-nm emission filter (24, 25). The image of the dermal microcirculatory bed was recorded using a silicon-intensified fluorescent camera (model C-2400-08; Hamamatsu Photonics, Hamamatsu City, Japan). Images of the dermal and skeletal muscle microcirculation were projected onto a monitor and recorded using a videocassette for playback analysis. Experiments were performed in cremaster preparations from sensitized/challenged or control mice to confirm that these two methods of visualizing leukocyte kinetics are comparable.
Single unbranched venules (2540 µm in diameter) were selected for vascular permeability and leukocyte kinetics analysis. Venular diameter (DV) was measured using a video caliper (Microcirculation Research Institute, Texas A&M University, College Station, TX). RBC velocity was measured on-line using an optical Doppler velocimeter (Microcirculation Research Institute) and was only measured for the skeletal muscle preparations, as determination of RBC velocity using fluorescence in the skin flap was not possible. Venular blood flow in the skeletal muscle was calculated from the product of cross-sectional area and mean RBC velocity (Vmean = VRBC/1.6), assuming cylindrical geometry. Venular wall shear rate (
) was calculated based on the Newtonian definition:
= 8 (Vmean/DV) (26).
Leukocyte kinetics
The number of rolling, adherent, and emigrated leukocytes was determined off-line during video playback analysis. Rolling flux was calculated as the number of cells passing a specific point in 3 min and expressed as cells/minute. A leukocyte was considered to be adherent if it remained stationary for at least 30 s, and total leukocyte adhesion was quantified as the number of adherent cells within a 100 µm length of venule. Leukocyte emigration was defined as the number of cells in the extravascular space within 200 x 300-µm area.
Vascular permeability
Vascular albumin leakage from the microcirculation to the extravascular space was used as a parameter of vascular permeability using a previously published protocol (27). Briefly, FITC-labeled BSA (25 mg/kg; Sigma-Aldrich) was administered i.v. to animals 15 min before the start of the experimental procedure. Fluorescence intensity (excitation wavelength, 420490 nm; emission wavelength, 520 nm) was detected using a silicon-intensified fluorescent camera (model C-2400-08; Hamamatsu Photonics), and images were recorded for playback analyses using a videocassette recorder. The fluorescent intensity of FITC-BSA within a defined area (10 x 50 µm) of the venule under study and in the adjacent perivascular interstitium (20 µm from venule) was measured during the control period and at various times after application of the Ag. This was accomplished with a video capture board (Visionplus AT-OFG; Imaging Technology, Bedford, MA) and a computer-assisted digital-imaging processor (Optimas; Bioscan, Edmonds, WA). The index of vascular albumin leakage (permeability index; percentage of ratio external/internal) was determined from the ratio of (interstitial intensity − background) (external) to (venular intensity − background) (internal) as previously reported (28).
Experimental protocol
Skeletal muscle and skin preparations in WT or W/Wv-sensitized or sham-sensitized mice were prepared for intravital microscopy, as previously described. To examine the immediate allergic response, mice were challenged with OVA (50 µg/ml) in the superfusion buffer after a control period was videotaped. Leukocyte kinetics and vascular permeability were measured in skin and cremaster preparations for at least 30 min following challenge. To examine the late phase response (4 h postchallenge), mice were given a local injection of OVA (intrascrotal, 10 µg; or intradermal, 100 µg) 4 h before observation. Sensitized sham-challenged and nonsensitized OVA-challenged mast cell-deficient or WT counterparts were used as controls. Data obtained from these control groups were not statistically different; therefore, for simplicity, only data from sensitized sham-challenged mice are presented. Leukocyte kinetics and vascular permeability were monitored in the skin or cremasteric microcirculation over a 1-h period 3.54.5 h postchallenge. In separate experiments, animals were pretreated with rabbit anti-mouse platelet serum (0.5 ml/Kg; Accurate Chemical and Scientific, Westbury, NY) 4 h before immediate OVA challenge or 1 h before OVA challenge to study the late response.
Platelet-endothelial cell interactions
In a separate set of experiments, platelet-endothelium interactions were observed in dermal and cremasteric microcirculation. Platelet-rich plasma was obtained by a method previously described (29). Briefly, mouse blood was obtained by cardiac puncture in acid-citrate-dextrose (ACD 1:9 blood v/v) and centrifuged at room temperature for 8 min at 1000 rpm. The plasma was removed and subsequently centrifuged at 1000 rpm for 3 min to obtain platelet-rich plasma, which was filtered through a Sepharose 2B column equilibrated with PIPES buffer (pH 7.0). The activation state of the isolated platelets was checked by examining surface P-selectin expression using FACS analysis, as previously described (29). Thrombin-stimulated samples were used as positive controls. Only nonactivated gel-filtered platelet preparations were used for the in vivo experiments. Gel-filtered platelets were fluorescently labeled with calcein AM (25 µg/ml; Molecular Probes, Eugene, OR) and diluted to 5 x 107 platelets/ml with PBS (pH 7.4), then injected i.v. in 0.20.4 ml vol.
Platelet-endothelial cell interactions were studied during the immediate hypersensitivity response in sensitized and nonsensitized WT mice. Platelet-Endothelial interactions were recorded before and after challenge with OVA buffer, as previously outlined. Platelets were determined to be interacting with the endothelium if they rolled for at least 30 µm along the vessel or were stationary for 10 s or longer. The number of interactions was quantified for 60 s at each time point in 250 µm of venule. Values have been adjusted and expressed as platelet interactions/100 µm/5 min to allow comparison of data with number of leukocyte interactions.
Circulating leukocyte and platelet counts
At the end of each experiment, whole blood was drawn via cardiac puncture. Total leukocyte counts were performed using a hemocytometer (Bright-line; Hausser Scientific, Horsham, PA). The number of platelets was counted using an automatic blood cell machine (STK-S; Coulter, Seattle, WA) in mice treated with anti-platelet Ab or their controls.
Statistical analysis
The results were expressed as means ± SEM. Statistical significance was assessed using Students t test or ANOVA with a Bonferoni correction where necessary. Statistical significance was taken at p < 0.05.
| Results |
|---|
|
|
|---|
Vascular permeability (Fig. 1) was observed in the dermal microvasculature of sensitized mast cell-deficient or WT mice. Recordings were made under baseline conditions and for 30 min following immediate Ag challenge. The late phase response was observed 4 h post-OVA challenge in a separate group of mice. Baseline vascular permeability in the skin was significantly higher in WT mice compared with W/Wv mice (Fig. 1) most likely due to preparation-induced stimulation of mast cells, as W/Wv sham controls had consistently lower permeability levels than WT sham controls (data not shown). In WT mice, vascular leakage of FITC-albumin increased after Ag challenge, reaching
75% by 30 min postchallenge. In contrast, no increase in vascular permeability was observed in W/Wv mice over the 30-min period studied. By 4 h post-Ag challenge, WT FITC-albumin leakage had returned to control levels and was not significantly different from W/Wv levels. The immediate increase in vascular permeability observed in WT mice resulted in an increase in leukocyte rolling flux (Fig. 2A) and adhesion (Fig. 2B) in WT mice 4 h post-OVA challenge. This increase in leukocyte recruitment during the late phase allergic reaction in the skin was entirely mast cell dependent, as no increase in leukocyte rolling or adhesion was observed in sensitized/challenged W/Wv mice (Fig. 2).
|
|
Vascular permeability can occur in sensitized skeletal muscle in response to allergen in the absence of mast cells
Table I outlines the hemodynamic parameters in cremaster microvasculature in sensitized WT and W/Wv mice 1 and 4 h postchallenge. White blood cell counts were similar in all groups studied. RBC velocity and vascular wall shear rates did not differ significantly between sham-challenged and OVA challenge WT mice or in W/Wv mice at either time point.
|
50% after 15 min. Baseline vascular permeability levels in sham-challenged WT mice are shown by (Fig. 3). FITC-albumin leakage in sham-challenged W/Wv mice remained below 10% for the duration of the experiment (data not shown). By 4 h postchallenge, FITC-albumin leakage in skeletal muscle had returned to control levels for both sensitized WT and W/Wv mice (Fig. 3). These data demonstrate that an increase in vascular permeability can occur in the absence of mast cells in muscle, suggesting a significant contribution to the immediate hypersensitivity response from another source.
|
Ag challenge in sensitized WT mice induced a significant increase in leukocyte rolling flux (Fig. 4A), which was accompanied by a significant increase in leukocyte adhesion and emigration 4 h post-OVA challenge (Fig. 4, B and C) in skeletal muscle.
|
Platelets are involved in the immediate increase in vascular permeability in sensitized skeletal muscle in response to allergen in the absence of mast cells
To study the role of platelets in vascular permeability and leukocyte recruitment during OVA-induced hypersensitivity, anti-platelet Ab was given to sensitized W/Wv mice before Ag challenge. Hemodynamic parameters (venular diameter, RBC velocity, and shear rate) were similar in W/Wv mice with and without anti-platelet Ab (Table II). Treatment with anti-platelet Ab reduced the total number of platelets in sensitized/challenged W/Wv mice by >99% (Fig. 5, inset), but did not alter the total number of circulating leukocytes (Table II).
|
|
Platelets play a role in leukocyte recruitment to skeletal muscle during the late phase response in mast cell-deficient mice
Fig. 6 illustrates leukocyte rolling, adherence, and emigration in sensitized W/Wv mice 4 h postchallenge. As previously noted, W/Wv mice were able to recruit leukocytes during the late phase response, as indicated by a significant increase in rolling (Fig. 6A), adhesion (Fig. 6B), and emigration (Fig. 6C) over sham-treated controls. When W/Wv mice were pretreated with anti-platelet Ab, a significant reduction in leukocyte rolling, but not adhesion, was noted. Platelet depletion, however, did significantly attenuate the number of leukocytes that eventually emigrated to the tissue, demonstrating a role for platelets in late phase leukocyte recruitment. This role for platelets was only unmasked in the absence of mast cells, as no inhibition in leukocyte recruitment was observed in WT mice depleted of platelets (data not shown).
|
Fig. 7 depicts platelet endothelium interactions (rolling and adherence) in sensitized WT mice in both dermal and skeletal muscle preparations before and 30 min after challenge with Ag. In skeletal muscle, an average of three platelet interactions was noted under baseline conditions; however, after 30-min OVA challenge, a significant increase in the number of platelet interactions was observed (25.0 ± 6.9 platelets/100 µm/5 min). An increase in platelet interactions was not observed in the cremaster of nonsensitized mice challenged with OVA (data not shown). In contrast, platelet interactions in the dermal microvasculature did not increase significantly after OVA challenge despite being more prevalent under baseline conditions.
|
![]()
| Discussion |
|---|
|
|
|---|
During classic allergic reactions, it is known that Ag-specific IgE binds to high affinity Fc
R1 receptors expressed on mast cells and basophils. When the allergen is subsequently encountered, it cross-links IgE and stimulates the mast cell to release histamine, serotonin, and a spectrum of preformed cytokines, as well as newly synthesized mediators such as platelet-activating factor, leukotrienes, and many others (4, 32, 33). Many of these chemicals have been shown to have profound effects on adhesion molecule expression and leukocyte recruitment in vivo (34, 35, 36). An alternate source for many of these, or similar mediators is the platelet. Platelets are anucleate cellular fragments containing
granules and dense granules that, upon stimulation, can release a variety of mediators capable of inducing vascular permeability and leukocyte recruitment (37). In this study, we demonstrated that the allergen-induced, mast cell-independent increase in vascular permeability could be abrograted by the depletion of circulating platelets (>99%), confirming that this cell fragment is an important pool for a mediator of vascular permeability. A likely candidate would be 5-HT because platelets are an important source for 5-HT in mast cell-deficient mice and their WT counterparts (6). In our study, however, depleting circulating platelets also prevented the late phase leukocyte recruitment, illustrating that chemotactic factors are also released from platelets. One such factor could be PAF, which has previously been shown to be involved in OVA-induced leukocyte adhesion in rat mestenteric venules (38). PAF has also been shown to be present in high levels in an IgE-dependent model of systemic anaphylaxis in both congenic and W/Wv mice (30). This study demonstrated that PAF released from a source other than mast cells was critical to the development of anaphylactic shock. Our study would suggest that that source for PAF or other chemotactic agents could be the circulating platelet.
Our study demonstrates that the role of mast cells in allergic inflammation is tissue specific. We and others (3) have shown that vascular permeability and leukocyte recruitment in the skin are entirely mast cell dependent. In addition, leukocyte recruitment into rat intestinal tissue is completely prevented in the absence of mast cells during OVA-induced late phase response (39). Yet, in this study in muscle, vascular permeability and leukocyte recruitment are only partially abrogated or unaffected, respectively, in the absence of mast cells. Similarly, leukocyte recruitment into lung is mast cell independent in this model of allergy (40, 41, 42). Previously, this model of immediate hypersensitivity in mice has been shown to be IgE mediated because the ability of serum from OVA-sensitized mice to induce a positive passive cutaneous anaphylaxis reaction was inactivated by heat (43). Although there is no evidence for Fc
RI on mouse platelets, platelet degranulation could occur by the binding of IgE through low affinity Fc
RII (CD23) or Fc
RIII (CD32) receptors (9, 15, 44, 45). In this study, treatment with anti-platelet serum in W/Wv mice returned vascular permeability to baseline levels, suggesting that mast cells and platelets play the major role in OVA-induced vascular permeability in mice. However, our results suggest that a minor role for other cell types in leukocyte recruitment cannot be discounted. Other potential cell types that can release potent biologically activated mediators through IgE-dependent mechanisms are the basophil via Fc
RI, or the eosinophil, macrophages, and lymphocytes via Fc
RII (CD23) (46). It should be noted, however, that sensitization of mice also results in the production of Ag-specific IgG Abs (15), which can induce passive systemic anaphylactic responses (47); because mouse platelets have Fc
R (14), we cannot discount a role for IgG in this allergic response.
Platelets may also play a more dominant role depending on the vascular bed being studied. It is clear from this study that sensitized platelets will roll and adhere to sensitized/challenged endothelium in the skeletal muscle, but not in the skin. These platelet interactions are not mediated through platelet P-selectin leukocyte adhesion because an increase in platelet interactions was also observed with P-selectin-deficient platelets. Although there appear to be more platelet-endothelium interactions under baseline conditions in the skin, there is no increase after challenge in sensitized mice. In contrast, the sensitized platelet population will interact in the cremaster only after Ag challenge. These data may suggest a difference in expression of endothelial adhesion molecules between the two tissues and are worthy of further investigation. Recently, Pitchford et al. (48) demonstrated a requirement for platelets in leukocyte recruitment to the lung in OVA-sensitized/challenged mice in the presence of mast cells. In our study, however, the role of platelets is only unmasked in the absence of mast cells because anti-platelet serum had no effect on immediate vascular permeability increases and subsequent leukocyte recruitment in WT mice (data not shown). These data illustrate a redundancy for the platelet response in skeletal muscle under normal conditions, which is only revealed when mast cells are depleted. This redundancy may become apparent and significant in situations in which therapeutic intervention is required to control allergic reactions. In addition, humans platelets do express Fc
RI receptors (49) and platelets may have a more dominant and/or synergistic role in hypersensitivity reactions clinically.
In conclusion, our data indicate that the platelet can play a compensatory role in the development of immediate allergic responses in skeletal muscle in the absence of mast cells. These data may go part way in explaining the phenomenon of anaphylactic shock observed in mast cell-deficient mice. In addition, it is clear that the level of platelet participation is dependent on the vascular bed studied. These data also emphasize the necessity to target more than simply the mast cell when designing therapeutic strategies to combat immediate allergic reactions.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Donna-Marie McCafferty, Gastrointestinal Research Group, Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada, T2N 4N1. E-mail address: dmmccaff{at}ucalgary.ca ![]()
3 Abbreviations used in this paper: 5-HT, 5-hydroxytryptamine; PAF, platelet-activating factor; WT, wild type. ![]()
Received for publication September 23, 2003. Accepted for publication February 5, 2004.
| References |
|---|
|
|
|---|
. J. Clin. Invest. 87:446.
RII. Blood Cells 19:353.[Medline]
RIII: assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J. Clin. Invest. 99:901.[Medline]
-induced leukocyte recruitment in the brain microvasculature. Circ. Res. 87:1141.
2-integrin in PAF-induced shock and intestinal injury. Am. J. Physiol. 270:G184.
4-integrin, P-selectin, and E-selectin in an allergic model of inflammation. J. Exp. Med. 185:1077.
RI
chain results in up-regulation of Fc
RIII-dependent mast cell degranulation and anaphylaxis: evidence of competition between Fc
RI and Fc
RIII for limiting amounts of FcR
and
chains. J. Clin. Invest. 99:915.[Medline]
RII/CD23: the low affinity receptor for IgE. Annu. Rev. Immunol. 8:623.[Medline]
This article has been cited by other articles:
![]() |
T. Shibamoto, T. Shimo, S. Cui, W. Zhang, H. Takano, Y. Kurata, and H. Tsuchida The roles of mast cells and Kupffer cells in rat systemic anaphylaxis Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2202 - R2209. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Schiemann, T. A. Grimm, J. Hoch, R. Gross, B. Lindner, F. Petersen, S. Bulfone-Paus, and E. Brandt Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G Blood, March 15, 2006; 107(6): 2234 - 2242. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |